[New therapeutic option for leukemia patients, with FLT3/Aurora kinase inhibitor, KW-2449: strategy and comparison with other kinase inhibitors].
Shiotsu
Yukimasa
Y
D000818:Animals; D064127:Aurora Kinases; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000235:genetics; D015470:Leukemia, Myeloid, Acute / Q000201:enzymology / Q000235:genetics; D009154:Mutation; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D011725:Pyridines; D011743:Pyrimidines; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology*
D004791:Enzyme Inhibitors; C523780:FI-700; D011725:Pyridines; D011743:Pyrimidines; D051941:fms-Like Tyrosine Kinase 3; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases